National
HRC president terminated after dispute with board on his role in Cuomo affair
David vows lawsuit to challenge termination
Human Rights Campaign President Alphonso David has been terminated as head of the nation’s leading LGBTQ group following a public dispute with the board over his role in the Andrew Cuomo scandal.
Jodie Patterson and Morgan Cox, co-chairs of the Human Rights Campaign, issued a statement late Monday explaining the decision that David, the first Black president of the LGBTQ group, was being terminated under the “for cause” provision of his contract.
“At HRC, we are fighting to bring full equality and liberation to LGBTQ+ people everywhere. That includes fighting on behalf of all victims of sexual harassment and assault,” Patterson and Cox wrote. “As outlined in the New York Attorney General report, Mr. David engaged in a number of activities in December 2020, while HRC President, to assist Gov. Cuomo’s team in responding to allegations by Ms. Boylan of sexual harassment. This conduct in assisting Governor Cuomo’s team, while president of HRC, was in violation of HRC’s Conflict of Interest policy and the mission of HRC.”
According to the statement, the boards for the Human Rights Campaign and Human Rights Campaign Foundation voted to terminate David. The board names Joni Madison, the current chief operating officer of the Human Rights Campaign as interim president effective immediately as board members engage in a search to replace David as president.
The decision to fire David comes after public sniping between him and the board co-chairs on the independent review the Human Rights Campaign initiated after he was named nearly a dozen times in the report issued by New York Attorney General Letitia James.
Both the Human Rights Campaign campaign board and the Human Rights Campaign voted to terminate David. A source familiar with the vote said it happened Monday night and no one voted “no” in either case. The campaign board vote was unanimous and there were two abstentions in foundation board vote, the source said.
The source familiar with the vote said David never told Human Rights Campaign he was helping Cuomo during his role as Human Rights Campaign president or talking to the New York attorney general. The first board members heard about it was when it hit the press, the source said.
According to a report in the New York Times, a person familiar with the deliberations among the HRC board said that David “never told the organization that he was helping to advise Mr. Cuomo when the accusations came to light.” Further, David didn’t consult the LGBTQ group’s counsel, or inform them he was going to be interviewed by James’s office, the Times reported.
The ignominious outcome of David’s tenure at the Human Rights Campaign comes after two years with him at the helm of the organization. Observers had high hopes for him as the first person of color to run the nation’s leading LGBTQ group, which he took into new directions with a foray into legal work on LGBTQ rights.
David, via Twitter, where his profile as of Tuesday morning still identifies him as HRC president, vowed to fight the decision to terminate him in court.
“As a Black, gay man who has spent his whole life fighting for civil and human rights, they cannot shut me up,” David wrote. “Expect a legal challenge.”
The board identified as reasons for termination David’s inability to serve as the public face of the Human Rights Campaign as well as “material damage” David has caused to the Human Rights Campaign as evidenced by media coverage and “hundreds of calls, emails and other negative communications HRC has received from staff, members of the Board of Governors, volunteers, program partners, general members, supporters, corporate partners, political figures, and more expressing serious concern with Mr. David’s conduct and its inconsistency with the values and mission of HRC.”
“This is a painful moment in our movement,” Patterson and Cox said. “While the Board’s decision is not the outcome we had ever envisioned or hoped for in terms of Mr. David’s tenure with HRC, his actions have put us in an untenable position by violating HRC’s core values, policies and mission.”
Over the weekend, David tweeted in a statement the board came to him late Friday telling him the review is completed, but suggested he resign even though they could produce no evidence of wrongdoing.
“I have the support of too many of our employees, board members and stakeholders to walk away quietly into the night,” David said. “I am not resigning.”
The next day, the board sent the email to their fellow members, saying they were “surprised and disappointed by the inaccuracies in his portrayal of events.” The email was shared with the Blade and three sources confirmed its accuracy.
Among the “mischaracterizations” identified by the board was David’s “assertion that there was ‘no indication of wrongdoing on his part.'”
David has said from the beginning he has committed no wrongdoing and wouldn’t resign as HRC president, even though other activists caught up in the scandal — Tina Tchen, president of “Time’s Up,” and Roberta Kaplan, board member of the same organization — made the decision to step down.
After the HRC board email became public on Monday, David issued a subsequent statement on Twitter: “The facts are that I was contacted by the board co-chairs late Friday night,” David wrote. “They told me that the Sidley Austin review was complete, but they would not provide the report to me or anyone. They gave me a deadline of 8 am the next morning to tell them whether I would resign. They didn’t offer a shred of evidence of any wrongdoing on my part when I asked repeatedly.”
At the time news of the New York attorney general report emerged, the board initially supported David, and renewed his contract for five years. The next week, however, the Human Rights Campaign board and David announced they had agreed to an independent review on his involvement in the Cuomo scandal that would be conducted by Sidley Austin LLP and last no longer than 30 days.
Sidley didn’t respond to multiple requests from the Washington Blade to comment over the weekend on the review. The board chairs have indicated the results of the review would be confidential.
According to the New York Times, the person familiar with the review, said there was no written report and there was never going to be one. Instead, there were oral presentations to the board. David is said to have given names to the board of people who would speak on his behalf during the investigation, in addition to the 10 hours he spent being interviewed, the Times reported.
Some legal experts had doubted the validity of a review by Sidley Austin on the basis it was among the legal firms agreeing in 2019 to help with the Human Rights Campaign entering into litigation to advance LGBTQ rights, an agreement David spearheaded upon taking the helm of the organization.
New York Attorney General Letitia James’s report on Cuomo names David nearly a dozen times. Among other things, the report indicated after his tenure as counselor to Cuomo, he kept the personnel file of an employee accusing the governor of sexual misconduct, then assisted in returning that file to Cuomo staffers seeking to leak it to the media in an attempt to discredit her.
(A representative has disputed the characterization of materials David kept as a personnel file, saying it was memorandum on an internal employment matter David kept because he, in part, worked on it. David has said he was legally required to return the material.)
Further, the report finds David allegedly said he would help find individuals to sign their names to a draft op-ed that sought to discredit the survivor but went unpublished, although he wouldn’t sign the document himself. Also, the report indicates David was involved in the discussions about secretly calling and recording a call between a former staffer and another survivor in a separate effort to smear her.
In response, David said he agreed to help with only one version of the letter that was more positive in nature and his part in the discussion about recording a survivor was limited to his role as counselor.
The nation’s leading LGBTQ group is now faced with the task of finding a new president at a time of significant challenges for the movement. The Equality Act is all but dead in Congress and numerous states have enacted laws targeting transgender youth, many of which are being challenged by litigation that was filed by the Human Rights Campaign.
Federal Government
Holiday week brings setbacks for Trump-Vance trans agenda
Federal courts begin to deliver end-of-year responses to lawsuits involving federal transgender healthcare policy.
While many Americans took the week of Christmas to rest and relax, LGBTQ politics in the U.S. continued to shift. This week’s short recap of federal updates highlights two major blows to the Trump-Vance administration’s efforts to restrict gender-affirming care for minors.
19 states sue RFK Jr. to end gender-affirming care ban
New York Attorney General Letitia James announced on Tuesday that the NYAG’s office, along with 18 other states (and the District of Columbia), filed a lawsuit to stop U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. from restricting gender-affirming care for minors.
In the press release, Attorney General James stressed that the push by the Trump-Vance administration’s crusade against the transgender community — specifically transgender youth — is a “clear overreach by the federal government” and relies on conservative and medically unvalidated practices to “punish providers who adhere to well-established, evidence-based care” that support gender-affirming care.
“At the core of this so-called declaration are real people: young people who need care, parents trying to support their children, and doctors who are simply following the best medical evidence available,” said Attorney General James. “Secretary Kennedy cannot unilaterally change medical standards by posting a document online, and no one should lose access to medically necessary health care because their federal government tried to interfere in decisions that belong in doctors’ offices. My office will always stand up for New Yorkers’ health, dignity, and right to make medical decisions free from intimidation.”
The lawsuit is a direct response to HHS’ Dec. 18 announcement that it will pursue regulatory changes that would make gender-affirming health care for transgender children more difficult, if not impossible, to access. It would also restrict federal funding for any hospital that does not comply with the directive. KFF, an independent source for health policy research, polling, and journalism, found that in 2023 federal funding covered nearly 45% of total spending on hospital care in the U.S.
The HHS directive stems directly from President Donald Trump’s Jan. 28 Executive Order, Protecting Children From Chemical and Surgical Mutilation, which formally establishes U.S. opposition to gender-affirming care and pledges to end federal funding for such treatments.
The American Medical Association, the nation’s largest and most influential physician organization, has repeatedly opposed measures like the one pushed by President Trump’s administration that restrict access to trans health care.
“The AMA supports public and private health insurance coverage for treatment of gender dysphoria and opposes the denial of health insurance based on sexual orientation or gender identity,” a statement on the AMA’s website reads. “Improving access to gender-affirming care is an important means of improving health outcomes for the transgender population.”
The lawsuit also names Oregon, Washington, California, Colorado, Connecticut, Delaware, the District of Columbia, Illinois, Maine, Maryland, Massachusetts, Michigan, Minnesota, New Mexico, Pennsylvania, Rhode Island, Vermont, and Wisconsin as having joined New York in the push against restricting gender-affirming care.
At the HHS news conference last Thursday, Jim O’Neill, deputy secretary of the department, asserted, “Men are men. Men can never become women. Women are women. Women can never become men.”
DOJ stopped from gaining health care records of trans youth
U.S. District Judge Cathy Bissoon blocked an attempt by the Department of Justice (DOJ) to gain “personally identifiable information about those minor transgender patients” from the University of Pittsburgh Medical Center (UPMC), saying the DOJ’s efforts “fly in the face of the Supreme Court.”
Journalist Chris Geidner originally reported the news on Dec. 25, highlighting that the Western District of Pennsylvania judge’s decision is a major blow to the Trump-Vance administration’s agenda to curtail transgender rights.
“[T]his Court joins the others in finding that the government’s demand for deeply private and personal patient information carries more than a whiff of ill intent,” Bissoon wrote in her ruling. “This is apparent from its rhetoric.”
Bissoon cited the DOJ’s “incendiary characterization” of trans youth care on the DOJ website as proof, which calls the practice politically motivated rather than medically sound and seeks to “…mutilate children in the service of a warped ideology.” This is despite the fact that a majority of gender-affirming care has nothing to do with surgery.
In United States v. Skrmetti, the Supreme Court ruled along party lines that states — namely Tennessee — have the right to pass legislation that can prohibit certain medical treatments for transgender minors, saying the law is not subject to heightened scrutiny under the Equal Protection Clause of the Fourteenth Amendment because it does not involve suspect categories like race, national origin, alienage, and religion, which would require the government to show the law serves a compelling interest and is narrowly tailored, sending decision-making power back to the states.
“The government cannot pick and choose the aspects of Skrmetti to honor, and which to ignore,” Judge Bissoon added.
The government argued unsuccessfully that the parents of the children whose records would have been made available to the DOJ “lacked standing” because the subpoena was directed at UPMC and that they did not respond in a timely manner. Bissoon rejected the timeliness argument in particular as “disingenuous.”
Bissoon, who was nominated to the bench by then-President Obama, is at least the fourth judge to reject the DOJ’s attempted intrusion into the health care of trans youth according to Geidner.
A Wider Bridge on Friday announced it will shut down at the end of the month.
The group that “mobilizes the LGBTQ community to fight antisemitism and support Israel and its LGBTQ community” in a letter to supporters said financial challenges prompted the decision.
“After 15 years of building bridges between LGBTQ communities in North America and Israel, A Wider Bridge has made the difficult decision to wind down operations as of Dec. 31, 2025,” it reads.
“This decision comes after challenging financial realities despite our best efforts to secure sustainable funding. We deeply appreciate our supporters and partners who made this work possible.”
Arthur Slepian founded A Wider Bridge in 2010.
The organization in 2016 organized a reception at the National LGBTQ Task Force’s Creating Change Conference in Chicago that was to have featured to Israeli activists. More than 200 people who protested against A Wider Bridge forced the event’s cancellation.
A Wider Bridge in 2024 urged the Capital Pride Alliance and other Pride organizers to ensure Jewish people can safely participate in their events in response to an increase in antisemitic attacks after Hamas militants attacked Israel on Oct. 7, 2023.
The Jewish Telegraphic Agency reported authorities in Vermont late last year charged Ethan Felson, who was A Wider Bridge’s then-executive director, with lewd and lascivious conduct after alleged sexual misconduct against a museum employee. Rabbi Denise Eger succeeded Felson as A Wider Bridge’s interim executive director.
A Wider Bridge in June honored U.S. Rep. Debbie Wasserman Schultz (D-Fla.) at its Pride event that took place at the Capital Jewish Museum in D.C. The event took place 15 days after a gunman killed two Israeli Embassy employees — Yaron Lischinsky and Sarah Milgrim — as they were leaving an event at the museum.
“Though we are winding down, this is not a time to back down. We recognize the deep importance of our mission and work amid attacks on Jewish people and LGBTQ people – and LGBTQ Jews at the intersection,” said A Wider Bridge in its letter. “Our board members remain committed to showing up in their individual capacities to represent queer Jews across diverse spaces — and we know our partners and supporters will continue to do the same.”
Editor’s note: Washington Blade International News Editor Michael K. Lavers traveled to Israel and Palestine with A Wider Bridge in 2016.
The White House
‘Trump Rx’ plan includes sharp cuts to HIV drug prices
President made announcement on Friday
President Donald Trump met with leaders from some of the world’s largest pharmaceutical companies at the White House on Friday to announce his new “Trump Rx” plan and outline efforts to reduce medication costs for Americans.
During the roughly 47-minute meeting in the Roosevelt Room, Trump detailed his administration’s efforts to cut prescription drug prices and make medications more affordable for U.S. patients.
“Starting next year, American drug prices will come down fast, furious, and will soon be among the lowest in the developed world,” Trump said during the meeting. “For decades, Americans have been forced to pay the highest prices in the world for prescription drugs by far … We will get the lowest price of anyone in the world.”
Trump signed an executive order in May directing his administration “to do everything in its power to slash prescription drug prices for Americans while getting other countries to pay more.”
“This represents the greatest victory for patient affordability in the history of American health care, by far, and every single American will benefit,” he added.
Several pharmaceutical executives stood behind the president during the announcement, including Sanofi CEO Paul Hudson, Novartis CEO Vas Narasimhan, Genentech CEO Ashley Magargee, Boehringer Ingelheim (USA) CEO Jean-Michel Boers, Gilead Sciences CEO Dan O’Day, Bristol Myers Squibb General Counsel Cari Gallman, GSK CEO Emma Walmsley, Merck CEO Robert Davis, and Amgen Executive Vice President Peter Griffith.
Also in attendance were Health and Human Services Secretary Robert F. Kennedy Jr., Commerce Secretary Howard Lutnick, Centers for Medicare and Medicaid Services Administrator Mehmet Oz, and Food and Drug Administration Commissioner Marty Makary.
Under the Trump Rx plan, the administration outlined a series of proposed drug price changes across multiple companies and therapeutic areas. Among them were reductions for Amgen’s cholesterol-lowering drug repatha from $573 to $239; Bristol Myers Squibb’s HIV medication reyataz from $1,449 to $217; Boehringer Ingelheim’s type 2 diabetes medication jentadueto from $525 to $55; Genentech’s flu medication xofluza from $168 to $50; and Gilead Sciences’ hepatitis C medication epclusa from $24,920 to $2,425.
Additional reductions included several GSK inhalers — such as the asthma inhaler advair diskus 500/50, from $265 to $89 — Merck’s diabetes medication januvia from $330 to $100, Novartis’ multiple sclerosis medication mayzent from $9,987 to $1,137, and Sanofi’s blood thinner plavix from $756 to $16. Sanofi insulin products would also be capped at $35 per month’s supply.
These prices, however, would only be available to patients who purchase medications directly through TrumpRx. According to the program’s website, TrumpRx “connects patients directly with the best prices, increasing transparency, and cutting out costly third-party markups.”
Kennedy spoke after Trump, thanking the president for efforts to lower pharmaceutical costs in the U.S., where evidence has shown that drug prices — including both brand-name and generic medications — are nearly 2.78 times higher than prices in comparable countries. According to the Pharmaceutical Research and Manufacturers of America, roughly half of every dollar spent on brand-name drugs goes to entities that play no role in their research, development, or manufacturing.
“This is affordability in action,” Kennedy said. “We are reversing that trend and making sure that Americans can afford to get the life-saving solutions.”
Gilead CEO Dan O’Day also spoke about how the restructuring of drug costs under TrumpRx, combined with emerging technologies, could help reduce HIV transmission — a virus that, if untreated, can progress to AIDS. The LGBTQ community remains disproportionately affected by HIV.
“Thank you, Mr. President — you and the administration,” O’Day said. “I think this objective of achieving the commitment to affordability and future innovation is extraordinary … We just recently launched a new medicine that’s only given twice a year to prevent HIV, and we’re working with Secretary Kennedy and his entire team, as well as the State Department, as a part of your strategy to support ending the epidemic during your term.
“I’ve never been more optimistic about the innovation that exists across these companies and the impact this could have on America’s health and economy,” he added.
Trump interjected, asking, “And that’s working well with HIV?”
“Yes,” O’Day replied.
“It’s a big event,” Trump said.
“It literally prevents HIV almost 100 percent given twice a year,” O’Day responded.
A similar anti-HIV medication is currently prescribed more than injectable form mentioned by O’Day. PrEP, is a medication regimen proven to significantly reduce HIV infection rates for people at high risk. Without insurance, brand-name Truvada can cost roughly $2,000 per month, while a generic version costs about $60 per month.
Even when medication prices are reduced, PrEP access carries additional costs, including clinic and laboratory fees, office visits, required HIV and sexually transmitted infection testing, adherence services and counseling, and outreach to potentially eligible patients and providers.
According to a 2022 study, the annual total cost per person for PrEP — including medication and required clinical and laboratory monitoring — is approximately $12,000 to $13,000 per year.
The TrumpRx federal platform website is now live at TrumpRx.gov, but the program is not slated to begin offering reduced drug prices until January.
Out actor talks lead role in ‘Fiddler on the Roof’
This gay author sees dead people
Holiday week brings setbacks for Trump-Vance trans agenda
Your guide to D.C.’s queer New Year’s Eve parties
Long-awaited ‘Pillion’ surpasses the sexy buzz
Reasons to be optimistic about 2026
Long-awaited ‘Pillion’ surpasses the sexy buzz
Trump’s ‘American people derangement syndrome’
Using movement to boost your mental health during holidays
